Abolis Biotechnologies, the French biotechnology company, has launched a platform to speed up discovery of microbial-derived cosmetic ingredients.
The Microbial Intelligence Explorer (MINE) is designed to help manufacturers and research and development (R&D) teams understand, interpret and act on complex microbial systems.
The tool supports product innovation, process development and scale-up by connecting microbial and multi-omics data – a combined set of information that merges two or more biological data layers – with experimental and industrial insight.
Microbial systems hold significant potential for industries seeking new approaches to product performance, supply chain resilience and more sustainable production, Abolis Biotechnologies claimed in a company statement.
Sylvia Julien, General Manager, MINE Business Unit, said: “The challenge in microbial biotechnologies lies in the difficulty of integrating the various pieces of information and, therefore, to know which signals matter and which hypotheses deserve further testing for product development.
“MINE gives teams a clearer way to navigate that complexity, helping them focus experimental work on the questions most likely to move a programme forward.”
The launch reflects Abolis Biotechnologies’ wider focus on making microbial biotechnology more industrially available.
How Abolis Biotechnologies’ new MINE platform could overhaul microbial ingredient discovery
Abolis Biotechnologies said for manufacturers and R&D teams, the challenge is not only identifying what microbes can do, but understanding which biological mechanisms and parameters are relevant at the metabolic level.
This also raises the question of which development routes warrant further investigation.
MINE was developed to address that gap by bringing together genomic exploration, multi-omics analysis and experimental interpretation, according to the French biotech firm.
It helps teams examine how individual strains contribute to producing molecules of interest, understanding interactions within more complex microbial systems.
MINE was based on Microbiome Studio, a machine learning (ML)-enabled analytical platform created out of the Metapath project, an industrial programme supported by the French government.
Initially created for Abolis’ own microbial biotechnology programmes, Microbiome Studio was refined through industrial collaborations before being developed into MINE for external R&D and open innovation teams.
MINE also makes microbial data more accessible to R&D and open innovation teams, without requiring every decision maker to be an omics or bioinformatics specialist.
Cyrille Pauthenier, co-founder and CEO of Abolis Biotechnologies, added: “MINE software release marks the point at which more than a decade of microbial biotechnology, data and industrial experience of Abolis becomes a platform to boost partners’ research and our own research.
“It strengthens Abolis’ ability to support decisions before, during and beyond experimentation, connecting biological evidence with the realities of validation, process development and scale-up.
“For our partners, that means a clearer route from microbial potential to an industrially relevant programme.”
Founded in 2014, Abolis Biotechnologies combines industrial biotechnology, microbiology, microbial fermentation, metabolism, robotics and intellectual property (IP) strategy.
Related content:
- Beiersdorf unveils Eucerin acne-prone skin treatment based on 20 years of microbiome research
- Nivea extends longevity offering with epigenetics eye serum featuring cryogenic technology
- Beiersdorf eyes acquisitions to reduce reliance on Nivea
- Nasal microbiome: Why research into the nose-brain axis will take beauty by storm
- Beiersdorf aims to make longevity skin care ‘accessible’ with Nivea innovation
- Unilever on uncovering the mysteries of the microbiome
- Beiersdorf cuts sales guidance as Nivea turnaround ‘remains too isolated’
